Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2018

View Archived Issues

Thinning out fat cells

Phase Ib data on intravenous dexmedetomidine support BioXcel's development of sublingual BXCL-501

ZYDG-2, a GPR40 agonist for potential treatment of type 2 diabetes

Introducing BioWorld Science: supporting R&D decisions through drug discovery and preclinical news

FDA grants approval for Qbrexza cloth as treatment of primary axillary hyperhidrosis

TAK-228 demonstrates potential for the treatment of NFE2L2-mutant squamous cell lung cancer

Vyxeos receives positive CHMP opinion

Epizyme patents KAT5 and KAT6A inhibitors

FDA lifts clinical hold for phase Ib trial of APTO-253

Cefepime/VNRX-5133 fixed-dose combination shows promise against resistant Gram-negative bacteria

Positive CHMP opinion granted for Mepsevii for the treatment of mucopolysaccharidosis VII

Laboratorios del Dr. Esteve presents new pyridazine derivatives for pain

Ocular Therapeutix announces NDA resubmission to the FDA for Dextenza

First-in-human study of D-0502 is enrolling participants

Patient enrollment ongoing in phase I/II study of SOBI-003 in pediatric MPS IIIA

Kymriah granted positive CHMP opinion for the treatment of two aggressive blood cancers

Refixia obtain Japanese approval for the treatment of hemophilia B

Phase II results presented from pivotal CAPTIVATE trial of ibrutinib plus venetoclax

CHMP adopts positive opinion for Yescarta

Lynparza receives Japanese approval for BRCA-mutated metastatic breast cancer

IMpassion130 study of Tecentriq plus Abraxane meets primary endpoint

EMA committee recommends marketing authorization for Veyvondi

JCR initiates phase II study of JR-141 as treatment of Hunter syndrome in Brazil

LEO Pharma initiates phase I study of LEO-138559

Imfinzi approved in Japan for the treatment of unresectable stage III NSCLC